Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.
Biologics
Forced expiratory volume in 1 s (FEV1)
Pulmonary function
Tezepelumab
Thymic stromal lymphopoietin (TSLP)
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
04
04
2023
accepted:
21
08
2023
medline:
24
11
2023
pubmed:
19
9
2023
entrez:
18
9
2023
Statut:
ppublish
Résumé
Severe asthma is associated with airway inflammation and airway obstruction. In the phase 3 NAVIGATOR study, tezepelumab treatment significantly improved pre-bronchodilator forced expiratory volume in 1 s (FEV NAVIGATOR was a multicenter, randomized, double-blind, placebo-controlled study. Patients (12-80 years old) receiving medium- or high-dose inhaled corticosteroids and at least one additional controller medication, with or without oral corticosteroids, were randomized 1:1 to tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Changes from baseline to week 52 in pre-bronchodilator FEV Tezepelumab treatment improved all evaluated lung function parameters over 52 weeks compared with placebo [least-squares mean difference (95% confidence interval): pre-bronchodilator FEV These findings further support the benefits of tezepelumab treatment in improving airflow limitation in patients with severe, uncontrolled asthma. NAVIGATOR (NCT03347279).
Identifiants
pubmed: 37723356
doi: 10.1007/s12325-023-02659-y
pii: 10.1007/s12325-023-02659-y
pmc: PMC10567907
doi:
Substances chimiques
Bronchodilator Agents
0
tezepelumab
RJ1IW3B4QX
Adrenal Cortex Hormones
0
Banques de données
ClinicalTrials.gov
['NCT03347279']
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
4957-4971Informations de copyright
© 2023. The Author(s).
Références
Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452–6.
doi: 10.1183/09031936.00165106
pubmed: 17537763
Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol. 2005;116(3):477–86.
doi: 10.1016/j.jaci.2005.07.011
pubmed: 16159612
Witt CA, Sheshadri A, Carlstrom L, Tarsi J, Kozlowski J, Wilson B, et al. Longitudinal changes in airway remodeling and air trapping in severe asthma. Acad Radiol. 2014;21(8):986–93.
doi: 10.1016/j.acra.2014.05.001
pubmed: 25018070
pmcid: 4100072
Tang M, Elicker BM, Henry T, Gierada DS, Schiebler ML, Huang BK, et al. Mucus plugs persist in asthma, and changes in mucus plugs associate with changes in airflow over time. Am J Respir Crit Care Med. 2022;205(9):1036–45.
doi: 10.1164/rccm.202110-2265OC
pubmed: 35104436
pmcid: 9851493
Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997–1009.
doi: 10.1172/JCI95693
pubmed: 29400693
pmcid: 5824874
Brown PJ, Greville HW, Finucane KE. Asthma and irreversible airflow obstruction. Thorax. 1984;39(2):131–6.
doi: 10.1136/thx.39.2.131
pubmed: 6701824
pmcid: 459739
Little SA, MacLeod KJ, Chalmers GW, Love JG, McSharry C, Thomson NC. Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med. 2002;112(6):446–52.
doi: 10.1016/S0002-9343(02)01047-1
pubmed: 11959054
Cassino C, Berger KI, Goldring RM, Norman RG, Kammerman S, Ciotoli C, et al. Duration of asthma and physiologic outcomes in elderly nonsmokers. Am J Respir Crit Care Med. 2000;162(4):1423–8.
doi: 10.1164/ajrccm.162.4.9912140
pubmed: 11029356
Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58(4):322–7.
doi: 10.1136/thorax.58.4.322
pubmed: 12668795
pmcid: 1746641
Sears MR. Lung function decline in asthma. Eur Respir J. 2007;30(3):411–3.
doi: 10.1183/09031936.00080007
pubmed: 17766631
Eschenbacher WL. Defining airflow obstruction. Chron Obstruct Pulmonary Dis. 2016;3(2):515.
Chae EJ, Kim T-B, Cho YS, Park C-S, Seo JB, Kim N, et al. Airway measurement for airway remodeling defined by post-bronchodilator FEV
doi: 10.4168/aair.2011.3.2.111
pubmed: 21461250
Sposato B, Scalese M, Ricci A, Rogliani P, Paggiaro P, et al. Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma. Clinl Respir J. 2021;15(2):237–43.
doi: 10.1111/crj.13325
Malerba M, Radaeli A, Olivini A, Damiani G, Ragnoli B, Sorbello V, et al. Association of FEF
doi: 10.1159/000443797
pubmed: 26855322
Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–92.
doi: 10.1080/14728222.2020.1783242
pubmed: 32567399
Li Y, Wang W, Lv Z, Li Y, Chen Y, Huang K, et al. Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo: a potential biomarker of severe refractory disease. J Immunol. 2018;200(7):2253–62.
doi: 10.4049/jimmunol.1701455
pubmed: 29453280
Gauvreau GM, O’Byrne PM, Boulet L-P, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–10.
doi: 10.1056/NEJMoa1402895
pubmed: 24846652
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–9.
doi: 10.1056/NEJMoa2034975
pubmed: 33979488
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.
doi: 10.1183/09031936.05.00034805
pubmed: 16055882
Tepper RS, Wise RS, Covar R, Irvin CG, Kercsmar CM, Kraft M, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129(3 Suppl):S65-87.
doi: 10.1016/j.jaci.2011.12.986
pubmed: 22386510
pmcid: 4263032
Santanello N, Zhang J, Seidenberg B, Reiss T, Barber B. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23–7.
doi: 10.1034/j.1399-3003.1999.14a06.x
pubmed: 10489824
Busse WW, Holgate ST, Wenzel SW, Klekotka P, Chon Y, Feng J, et al. Biomarker profiles in asthma with high vs low airway reversibility and poor disease control. Chest. 2015;148(6):1489–96.
doi: 10.1378/chest.14-2457
pubmed: 26226215
pmcid: 4665740
Tamura K, Shirai T, Hirai K, Nakayasu H, Takahashi S, Kishimoto Y, et al. Mucus plugs and small airway dysfunction in asthma, COPD, and asthma-COPD overlap. Allergy Asthma Immunol Res. 2022;14(2):196.
doi: 10.4168/aair.2022.14.2.196
pubmed: 35255537
pmcid: 8914605
Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–312.
doi: 10.1016/S2213-2600(21)00226-5
pubmed: 34256031
Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:10834.
Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:3559.
Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019;56(10):1110–9.
doi: 10.1080/02770903.2018.1520865
pubmed: 30273510
Menzies-Gow A, Steenkamp J, Singh S, Erhardt W, Rowell J, Rane P, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679–90.
doi: 10.1080/13696998.2022.2074195
pubmed: 35570578
Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16.
doi: 10.1111/j.1398-9995.2004.00772.x
pubmed: 15679715
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9.
doi: 10.1016/S0140-6736(12)60988-X
pubmed: 22901886
Mathur SK, Modena BD, Coumou H, Barker P, Kreindler JL, Zangrilli JG. Postbronchodilator lung function improvements with benralizumab for patients with severe asthma. Allergy. 2020;75(6):1507.
doi: 10.1111/all.14178
pubmed: 31925789
Svenningsen S, Haider E, Boylan C, Mukherjee M, Eddy RL, Capaldi DP, et al. CT and functional MRI to evaluate airway mucus in severe asthma. Chest. 2019;155(6):1178–89.
doi: 10.1016/j.chest.2019.02.403
pubmed: 30910637
Lubrano L, Volpi S, Andreatta E, Borruso A, Spinelli E, Vassanelli C, et al. Lung clearance index in asthmatic patients. Eur Respir Soc. 2016;2:2.
Cherrez-Ojeda I, Robles-Velasco K, Osorio MF, Calderon J, Bernstein JA. Current needs assessment for using lung clearance index for asthma in clinical practice. Curr Allergy Asthma Rep. 2022;22(2):13–20.
doi: 10.1007/s11882-022-01025-2
pubmed: 35072930
Cottee AM, Seccombe LM, Thamrin C, King GG, Peters MJ, Farah CS. Bronchodilator response assessed by the forced oscillation technique identifies poor asthma control with greater sensitivity than spirometry. Chest. 2020;157(6):1435–41.
doi: 10.1016/j.chest.2019.12.035
pubmed: 31982392
pmcid: 7268434